

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/581,532
Filing Date	June 20, 2007
First Named Inventor	Phillip Robert Bennett
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	06-404

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	* ⁶
		Country Code ³ "Number ⁴ " "Kind Code ⁵ (if known)"				
	1	GB 2 293 101 A	03-20-1996	British Tech Group		
	2	WO 99/18942	04-22-1999	Imperial College Innovations LTD		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 10/581,532

Filing Date June 20, 2007

First Named Inventor Phillip Robert Bennett

Art Unit 1614

Examiner Name TBA

Attorney Docket Number 06-404

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Lappas Martha, et al., "Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro" BIOLOGY OF REPRODUCTION, (2002), vol. 67, no. 2, pages 668-673.	
	4	Straus D. S., et al., "Cyclopentenone Prostaglandins: New Insights on Biological Activities and Cellular Targets" MEDICINAL RESEARCH REVIEWS, (2001), vol. 21, no. 3, pages 185-210.	
	5	Lappas M. Et al., "'Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma?: Effect of 15-deoxy-delta12,14>PGJ2 and troglitazone', JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (2002), vol. 87, no. 10, pages 4667-4672.	
	6	Gross G, et al., "Inhibition of Cyclooxygenase-2 Prevents Inflammation-Mediated Preterm Labor in the Mouse", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, (2000), vol. 278, no. 6, PART 2, pages R1415-R1423.	

Examiner
SignatureDate
Considered